Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 21
---
 Depositary Shares
to Melior. Between December 21, 2023 and April 1, 2025, we have issued 738,002,400 Ordinary Shares upon the exercise of December 2023
Private Placement Pre-Funded Warrants issued to the Secured Noteholders.

| 16 |

On December 21, 2023, we completed
the closing of an underwritten public offering, pursuant to which we issued and sold (i) 43,555 Class A units, or Class A Units, at a
public offering price of $50.00 per Class A Unit, with each Class A Unit consisting of (a) one Depositary Share, (b) one Series E warrant,
or Series E Warrant, and (c) one Series F warrant, or Series F Warrant, and (ii) 76,447 Class B units, or Class B Units, at a public offering
price of $26.9999 per Class B Unit, with each Class B Unit consisting of (a) one pre-funded warrant, exercisable for one Depositary Share,
(b) one Series E Warrant, and (c) one Series F Warrant. The aggregate gross proceeds to the Company were approximately $6.0 million. Additionally,
we issued warrants to purchase 4,800 of our Depositary Shares in connection with the offering to the underwriter, or the December 2023
Underwriter Warrants.

On February 26, 2024, in connection
with our obligations under a license agreement with Melior, we issued 14,177 Depositary Shares to Bukwang Pharmaceutical Co. Ltd.

On April 29, 2024, in connection
with the closing of the transaction contemplated by the license and collaboration agreement with Rapamycin Holdings, Inc. d/b/a Emtora
Biosciences, Inc., or Emtora, we issued 15,136 Depositary Shares to Emtora.

On May 24, 2024, in connection
with the transactions contemplated by certain warrant inducement letters, we issued an aggregate of 124,181 Depositary Shares to certain
holders of our Series E Warrants and Series F Warrants, upon the exercise of 62,906 Series E Warrants and 61,275 Series F Warrants, at
an exercise price of $37.50 per share. In addition, we issued to such holders an aggregate of 94,358 Series G warrants, or the Series